AGTX (Agentix) Debt-to-Revenue : N/A (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Agentix Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Agentix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.17 Mil. Agentix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.00 Mil. Agentix's annualized Revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Agentix Debt-to-Revenue Historical Data

The historical data trend for Agentix's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Debt-to-Revenue Chart

Agentix Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Mar23

Mar24

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

Agentix Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Agentix's Debt-to-Revenue

For the Biotechnology subindustry, Agentix's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Agentix's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Agentix's Debt-to-Revenue falls into.

Agentix Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Agentix's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.143	+	0)	/	N/A
	=	N/A

Agentix's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.173	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Agentix Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Agentix's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Agentix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629

Website

https://www.agentixcorp.com

Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.

Executives

Thomas E Puzzo	10 percent owner	4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter	director, 10 percent owner, officer: President, CEO, CFO, Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc	10 percent owner	320 PARK AVE, NEW YORK NY 10022
Scott B Stevens	director, officer: President and Director	9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen	director, officer: Secretary and Treasurer	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust	director	14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius	director, 10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han	10 percent owner	32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix Headlines

No Headlines